

1376

## REGULATION OF NON-CANONICAL PROTEINS ENCODED BY SMALL OPEN READING FRAMES VIA NONSENSE-MEDIATED DECAY PATHWAY

<sup>1</sup>Parthiban Periasamy\*, <sup>1</sup>Craig Joseph, <sup>2</sup>Harsha Gowda, <sup>1</sup>Joe Yeong. <sup>1</sup>A\*-STAR, Singapore, Singapore; <sup>2</sup>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

**Background** Immunotherapy has shown great promise in the treatment of cancer, but its effectiveness is limited by the availability of neoantigens on cell surfaces.<sup>1</sup> While PD-L1 inhibitors have demonstrated encouraging outcomes in clinical trials for advanced melanoma and non-small cell lung cancer, their applicability is restricted to a select group of patients.<sup>2</sup> In a recent study by Chong et al.,<sup>3</sup> it was found that non-canonical proteins encoded by the human genome may possess peptides that can act as neoantigens, providing a promising avenue for immunotherapeutic targeting. However, these proteins tend to be expressed at low abundance thereby reducing their abundance and restricting their utility.

**Methods** In the present study, we adopted a proteogenomics methodology to identify multiple non-canonical proteins synthesized by breast cancer cell lines. To investigate whether the production of intracellular non-canonical proteins is enhanced and whether non-canonical protein-derived neoantigens are upregulated, we perturbed a conserved quality control mechanism within cells.

**Results** These non-canonical proteins exhibited low abundance and inconsistent expression patterns, which could be attributed to the degradation of these proteins by conserved quality control mechanisms in cells, such as the nonsense-mediated decay (NMD) pathway. By targeting this pathway through the knockdown of UPF1, a key regulator of NMD,<sup>4</sup> we were able to increase the levels of non-coding transcripts and non-canonical proteins. We also observed increased expression of unannotated transcripts and human leukocyte antigen transcripts associated with antigen presentation. Our in vivo analysis of UPF1 protein expression in triple-negative breast cancer (TNBC) patient tumor samples (n=48) demonstrated that UPF1 is highly expressed at the protein level compared to adjacent stroma. Moreover, our expanded analysis of UPF1 transcript expression across multiple cancer types revealed that UPF1 is highly expressed in cancer tissues compared to adjacent normal tissue.

**Conclusions** Our observations suggest that TNBC and other cancer types upregulate the NMD pathway to suppress the production of mutant transcripts and non-canonical proteins, which could potentially mask neoantigens presentation on cancer cell surfaces. By modulating the expression level of UPF1, we could potentially increase the reservoir of neoantigens and enhance neoantigen presentation, ultimately augmenting immunotherapeutic responses in cancer patients.

**Acknowledgements** We would like to express our gratitude to several parties for their valuable contributions to this work. Firstly, we would like to thank Prof. Khanna from QIMRB for providing breast cancer cell lines, and QIMRB Scientific Services for assisting with mycoplasma testing and cell line authentication. Additionally, we would like to acknowledge the excellent administrative and technical support provided by the QIMRB sequencing facility and high-performance computing department. The mIHC work was funded by a grant from the A\*STAR BIOMEDICAL ENGINEERING PROGRAMME (Project No: C211318003) of the Singapore National Medical Research Council (MOH-000323-00, OFYIRG19may-0007) and IAF-PP (HBMSDomain): H19/01/a0/024-SInGapore

ImmuNogrAm for Immuno-Oncology (SIGNAL) awarded to J. Y. Finally, we would like to extend our gratitude to H.G. NHMRC funding. H.G. is a NHMRC R.D. Wright Fellow.

## REFERENCES

- Westcott Peter MK, et al. 'Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.' *Nature cancer* 2021;**2**(10):1071–1085.
- Li Guanqiao, et al. 'Comparing development strategies for PD1/PDL1-based immunotherapies.' *Nature reviews. Drug discovery* 2022;**21**(7):484.
- Chong Chloe, et al. 'Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes.' *Nature communications* **11**(1):1293.
- Lykke-Andersen, Søren, Torben Heick Jensen. 'Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes.' *Nature reviews. Molecular cell biology* 2015;**16**(11):665–77.

<http://dx.doi.org/10.1136/jitc-2023-SITC2023.1376>